Investigating the 'liquidesolid interface' in the comprehensive genomic profiling of metastatic colorectal cancer for guiding treatmentdwhere do we draw the line?

被引：0

作者：

Tan, I. Beehuat ^{[1
]}

Lui, R. ^{[2
]}

Yan, K. ^{[3
]}

Lam, R. ^{[4
]}

Ma, B. B. Y. ^{[4
]}

机构：

[1] Natl Canc Ctr, Div Med Oncol, Singapore, Singapore

[2] Prince Wales Hosp, Dept Med & Therapeut, Hong Kong, Peoples R China

[3] Chinese Univ Hong Kong, Hong Kong Canc Inst, Sir YK Pao Ctr Canc, State Key Lab Translat Oncol,Dept Clin Oncol, Hong Kong, Peoples R China

[4] Chinese Univ Hong Kong, Fac Med, Hong Kong, Peoples R China

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷 / 12期

关键词：

D O I：

10.1016/j.annonc.2024.10.019

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1067 / 1070

页数：4

共 14 条

[1] Clinical Validation of Plasma-Based Genotyping for RAS and BRAF V600E Mutation in Metastatic Colorectal Cancer: SCRUM-Japan GOZILA Substudy [J].

Aoki, Yu ;

Nakamura, Yoshiaki ;

Denda, Tadamichi ;

Ohta, Takashi ;

Esaki, Taito ;

Shiozawa, Manabu ;

Yamaguchi, Kensei ;

Yamazaki, Kentaro ;

Sunakawa, Yu ;

Kato, Takeshi ;

Okano, Naohiro ;

Taniguchi, Hiroya ;

Sato, Taro ;

Oki, Eiji ;

Nishina, Tomohiro ;

Komatsu, Yoshito ;

Matsuhashi, Nobuhisa ;

Goto, Masahiro ;

Yasui, Hisateru ;

Ohtsubo, Koushiro ;

Moriwaki, Toshikazu ;

Takahashi, Naoki ;

Horita, Yosuke ;

Boku, Shogen ;

Wakabayashi, Masashi ;

Ikeno, Takashi ;

Mitani, Ryuta ;

Yuasa, Mihoko ;

Yoshino, Takayuki .

JCO PRECISION ONCOLOGY, 2023, 7

[2] Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up [J].

Cervantes, A. ;

Adam, R. ;

Rosello, S. ;

Arnold, D. ;

Normanno, N. ;

Taieb, J. ;

Seligmann, J. ;

De Baere, T. ;

Osterlund, P. ;

Yoshino, T. ;

Martinelli, E. .

ANNALS OF ONCOLOGY, 2023, 34 (01) :10-32

[3] Transcriptional Profiling and Consensus Molecular Subtype Assignment to Understand Response and Resistance to Anti-Epidermal Growth Factor Receptor Therapy in Colorectal Cancer [J].

Chowdhury, Saikat ;

Gupta, Ria ;

Millstein, Joshua ;

Lin, Kangyu ;

Haridas, Valsala ;

Zeineddine, Mohammad A. ;

Parseghian, Christine ;

Lenz, Heinz-Josef ;

Kopetz, Scott ;

Shen, John Paul .

JCO PRECISION ONCOLOGY, 2023, 7

[4] Comprehensive genomic profiling by liquid biopsy captures tumor heterogeneity and identifies cancer vulnerabilities in patients with RAS/BRAFV600E wild-type metastatic colorectal cancer in the CAPRI 2-GOIM trial [J].

Ciardiello, D. ;

Bielo, L. Boscolo ;

Napolitano, S. ;

Martinelli, E. ;

Troiani, T. ;

Nicastro, A. ;

Latiano, T. P. ;

Parente, P. ;

Maiello, E. ;

Avallone, A. ;

Normanno, N. ;

Pisconti, S. ;

Nisi, C. ;

Bordonaro, R. ;

Russo, A. E. ;

Tamburini, E. ;

Toma, I. ;

Lotesoriere, C. ;

Vallarelli, S. ;

Zampino, M. G. ;

Fazio, N. ;

Curigliano, G. ;

De Vita, F. ;

Ciardiello, F. ;

Martini, G. .

ANNALS OF ONCOLOGY, 2024, 35 (12) :1105-1115

[5] The genomic landscape of 2,023 colorectal cancers [J].

Cornish, Alex J. ;

Gruber, Andreas J. ;

Kinnersley, Ben ;

Chubb, Daniel ;

Frangou, Anna ;

Caravagna, Giulio ;

Noyvert, Boris ;

Lakatos, Eszter ;

Wood, Henry M. ;

Thorn, Steve ;

Culliford, Richard ;

Arnedo-Pac, Claudia ;

Househam, Jacob ;

Cross, William ;

Sud, Amit ;

Law, Philip ;

Ni Leathlobhair, Maire ;

Hawari, Aliah ;

Woolley, Connor ;

Sherwood, Kitty ;

Feeley, Nathalie ;

Guel, Gueler ;

Fernandez-Tajes, Juan ;

Zapata, Luis ;

Alexandrov, Ludmil B. ;

Murugaesu, Nirupa ;

Sosinsky, Alona ;

Mitchell, Jonathan ;

Lopez-Bigas, Nuria ;

Quirke, Philip ;

Church, David N. ;

Tomlinson, Ian P. M. ;

Sottoriva, Andrea ;

Graham, Trevor A. ;

Wedge, David C. ;

Houlston, Richard S. .

NATURE, 2024, 633 (8028) :127-+

[6] Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis [J].

De Roock, Wendy ;

Claes, Bart ;

Bernasconi, David ;

De Schutter, Jef ;

Biesmans, Bart ;

Fountzilas, George ;

Kalogeras, Konstantine T. ;

Kotoula, Vassiliki ;

Papamichael, Demetris ;

Laurent-Puig, Pierre ;

Penault-Llorca, Frederique ;

Rougier, Philippe ;

Vincenzi, Bruno ;

Santini, Daniele ;

Tonini, Giuseppe ;

Cappuzzo, Federico ;

Frattini, Milo ;

Molinari, Francesca ;

Saletti, Piercarlo ;

De Dosso, Sara ;

Martini, Miriam ;

Bardelli, Alberto ;

Siena, Salvatore ;

Sartore-Bianchi, Andrea ;

Tabernero, Josep ;

Macarulla, Teresa ;

Di Fiore, Frederic ;

Gangloff, Alice Oden ;

Ciardiello, Fortunato ;

Pfeiffer, Per ;

Qvortrup, Camilla ;

Hansen, Tine Plato ;

Van Cutsem, Eric ;

Piessevaux, Hubert ;

Lambrechts, Diether ;

Delorenzi, Mauro ;

Tejpar, Sabine .

LANCET ONCOLOGY, 2010, 11 (08) :753-762

[7] Molecular screening with liquid biopsy for anti-EGFR retreatment in metastatic colorectal cancer: preliminary data from the randomized phase 2 PARERE trial [J].

Germani, Marco Maria ;

Vetere, Guglielmo ;

Giordano, Mirella ;

Ciraci, Paolo ;

Capone, Iolanda ;

Tamborini, Elena ;

Conca, Elena ;

Busico, Adele ;

Pietrantonio, Filippo ;

Piva, Vittoria Matilde ;

Boccaccino, Alessandra ;

Simionato, Francesca ;

Bortolot, Martina ;

Manca, Paolo ;

Lonardi, Sara ;

Conca, Veronica ;

Borelli, Beatrice ;

Carullo, Martina ;

Del Re, Marzia ;

Fontanini, Gabriella ;

Rossini, Daniele ;

Cremolini, Chiara .

FRONTIERS IN ONCOLOGY, 2024, 13

[8] Efficacy and safety of a biomarker-driven cetuximab-based treatment regimen over 3 treatment lines in mCRC patients with RAS/BRAF wild type tumors at start of first line: The CAPRI 2 GOIM trial [J].

Martini, Giulia ;

Ciardiello, Davide ;

Napolitano, Stefania ;

Martinelli, Erika ;

Troiani, Teresa ;

Latiano, Tiziana Pia ;

Avallone, Antonio ;

Normanno, Nicola ;

Di Maio, Massimo ;

Maiello, Evaristo ;

Ciardiello, Fortunato .

FRONTIERS IN ONCOLOGY, 2023, 13

[9] Liquid biopsies to monitor and direct cancer treatment in colorectal cancer [J].

Mauri, Gianluca ;

Vitiello, Pietro Paolo ;

Sogari, Alberto ;

Crisafulli, Giovanni ;

Sartore-Bianchi, Andrea ;

Marsoni, Silvia ;

Siena, Salvatore ;

Bardelli, Alberto .

BRITISH JOURNAL OF CANCER, 2022, 127 (03) :394-407

[10] CAVE-2 (Cetuximab-AVElumab) mCRC: A Phase II Randomized Clinical Study of the Combination of Avelumab Plus Cetuximab as a Rechallenge Strategy in Pre-Treated RAS/BRAF Wild-Type mCRC Patients [J].